CoChat
Sign Up
Cited by 475Schizophrenia research and treatmentAttention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional Development

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Double-Blind, Placebo-Controlled Study of Risperidone for the Treatment of Disruptive Behaviors in Children With Subaverage Intelligence

Aman, Michael G., De Smedt, Goedele, Derivan, Albert, Lyons, Ben, Findling, Robert L., Risperidone Disruptive Behavior Study Group·2002·American Journal of Psychiatry
DOI 10.1176/appi.ajp.159.8.1337
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The short-term efficacy and safety of risperidone in the treatment of disruptive behaviors was examined in a well-characterized cohort of children with subaverage intelligence. METHOD: In this 6-week, multicenter, double-blind, parallel-group study of 118 children (aged 5-12 years) with severely disruptive behaviors and subaverage intelligence (IQ between 36 and 84, inclusive), the subjects received 0.02-0.06 mg/kg per day of risperidone oral solution or placebo. The a priori primary efficacy measure was the change in score from baseline to endpoint on the conduct problem subscale of the Nisonger Child Behavior Rating Form. RESULTS: The risperidone group showed significantly greater improvement than did the placebo group on the conduct problem subscale of the Nisonger Child Behavior Rating Form from week 1 through endpoint (change in score of -15.2 and -6.2, respectively). Risperidone was also associated with significantly greater improvement than placebo on all other Nisonger Child Behavior Rating Form subscales at endpoint, as well as on the Aberrant Behavior Checklist subscales for irritability, lethargy/social withdrawal, and hyperactivity; the Behavior Problems Inventory aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; and the Clinical Global Impression change score. The most common adverse effects reported during risperidone treatment were headache and somnolence. The extrapyramidal symptom profile of risperidone was comparable to that of placebo. Mean weight increases of 2.2 kg. and 0.9 kg occurred in the risperidone and placebo groups, respectively. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of severely disruptive behaviors in children with subaverage IQ.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.159.8.1337

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 49 references

Research works printed but not linked: 1

  1. Chouinard G, Ross-Chouinard A, Annable L, Jones B: Extrapyramidal Symptom Rating Scale (abstract). Can J Neurol Sci 1980; 7:233

Cited by

Sorted by citations

Items 101–200 of 472

Related

See all

Metadata

Authors
Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group
Affiliations
The Ohio State University (US)
ORCID
Findling, Robert L.
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2002-08-01
Volume
159
Issue
8
Pages
1337-1346
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.159.8.1337
OpenAlex
W2133752375
Cited by
475
References
49
Citations by year
2026: 4 · 2025: 7 · 2024: 10 · 2023: 8 · 2022: 16 · 2021: 6 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 13 · 2016: 12 · 2015: 17 · 2014: 17 · 2013: 26 · 2012: 20
FWCI
18.17
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
risperidone, disruptive behavior, children with intellectual disabilities, antipsychotic drugs, conduct problems, Aberrant Behavior Checklist, extrapyramidal symptoms, weight gain, adverse effects, hyperactivity, aggression
MeSH terms
Aggression, Child, Double-Blind Method, Female, Humans, Male, Intellectual Disability, Personality Assessment, Placebos, Antipsychotic Agents, Comorbidity, Treatment Outcome, Risperidone, Conduct Disorder, Attention Deficit and Disruptive Behavior Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review